CHAPTER 5 116 0 10 20 30 40 50 60 Low Intermediate High-intermediate High Advanced/metastatic % PRP53-abn L1CAM+ ERESMO-ESTRO-ESGO risk classification groups Figure 1 Figure 1. Immunohistochemical expression of p53, L1CAM and ER/PR in relation to the ESMOESGO-ESTRO risk classification. Abbreviations: L1CAM, L1 cell-adhesion molecule; ER/PR, estrogen receptor/progesterone receptor; ESMOESGO-ESTRO, European Society for Medical Oncology - European Society of Gynaecological Oncology - European SocieTy for Radiotherapy & Oncology. Immunohistochemical expression in addition to ESMO-ESGO-ESTRO risk classification The RFS according to the ESMO-ESGO-ESTRO risk groups and IHC expression of p53, L1CAM and ER/PR in the ESMO ‘high and advanced/metastatic’ risk group are shown in Figure 2. The ESMO-ESGO-ESTRO risk classification group ‘high and advanced/ metastatic’ are significantly associated with poor RFS (p<0.001) (Figure 2A). Within the ‘high and advanced/metastatic’ risk group, patients with abnormal IHC expression of; p53, L1CAM and ER/PR, p53 and L1CAM, L1CAM and ER/PR, and only ER/PR have the lowest RFS, compare to patients with abnormal expression of; p53 and ER/PR, only p53 and only L1CAM (Figure 2B). Detailed survival curves of the ESMO-ESGO-ESTRO risk groups in relation to IHC expression are demonstrated in Figure 3A-C. Patients with abnormal IHC expression (p53-abn, L1CAM+ or ER/PR-) and ESMO-ESGO-ESTRO risk group ‘high and advanced/metastatic’ show the lowest RFS compared with the other subgroups.
RkJQdWJsaXNoZXIy MTk4NDMw